Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini-CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information:
Caravan Biologix, Inc.:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oliver Bäte, Allianz CEO, Addresses United Nations Climate Ambition Summit21.9.2023 17:00:00 CEST | Press release
Yesterday, leaders from 34 governments along with seven non-government bodies, including Californian governor Gavin Newsom, London mayor Sadiq Khan, the World Bank president, the Chief Executive of insurer Allianz, and the head of the UN’s Green Climate Fund, addressed the summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230921957666/en/ Oliver Baete, Allianz CEO, speaking at the UN Climate Ambitions Summit on September 20, 2023. (Photo: Business Wire) Allianz CEO Oliver Bäte was representing the UN-Convened Net-Zero Asset Owner Alliance (NZAOA) and Allianz's commitment as a "first mover and doer" in the global effort to combat the climate crisis. The transcript of Oliver Bäte’s speech follows. Dear excellencies, ladies and gentlemen, Since we last came together to announce the launch of the UN-Convened Net Zero Asset Owner Alliance in 2019 in this building, the world has changed profoundly. We have not talked about th
ProAmpac Joins Nestlé to Celebrate 2023 Digital Labels & Packaging Awards21.9.2023 16:41:00 CEST | Press release
ProAmpac, a leader in flexible packaging and material science, is proud to announce its partnership with Nestlé in celebrating their joint recognition for the prestigious 2023 Digital Labels & Packaging Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230921516289/en/ Teams from ProAmpac’s Grimsby site and Nestlé UK Celebrate the 2023 Digital Labels & Packaging Award (Photo: Business Wire) The annual Print Award, hosted by Digital Labels & Print Magazine (DLPM), recognizes the finest achievements in digital printing as applied to packaging. During the Awards Gala held on June 29 at the Kia Oval in London, DLPM announced that Nestlé Splash – KitKat, developed in collaboration with ProAmpac, emerged as a top contender in the Application Excellence – Primary Packaging category. "We are honored to have partnered with Nestlé on this packaging achievement," expressed Adam Grose, Chief Commercial Officer at ProAmpac. "Being na
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses21.9.2023 16:00:00 CEST | Press release
Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to help prevent the spread of negatively charged viruses such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations. In development since 2022, the project has so far seen the completion of safety assessment utilizing intranasal administration at Altasciences’ preclinical site in Columbia, MO. A cardiovascular study was also completed at Altasciences’ preclinical facility in Scranton, PA. Bioanalytical sample analysis for the GLP studies is currently ongoing. “We
Nitek: End of the Road for Copycats21.9.2023 15:00:00 CEST | Press release
Nitek, Inc. (“Nitek”), a pioneering American company in UV LEDs, has announced that it filed a patent infringement lawsuit against Photon Wave Co., Ltd. (“Photon Wave”), a Korean UV LED manufacturer in the Eastern District of Texas. In the complaint, Nitek asserts that LED products of ams OSRAM, a German LED company, use Photon Wave’s infringing LEDs. Nitek also contends that Photon Wave has failed to cease selling infringing products, even after getting continuous warning notices of the patent infringement, and therefore Nitek is not only seeking a permanent injunction against the sales of infringing products but also pursuing 3 times damages for willful patent infringement. Nitek has previously successfully won its patent lawsuit against another international LED maker, and continues its enforcement against other infringers. Sensor Electronic Technology, Inc. (“SETi”), an affiliate of Nitek, has also obtained a permanent injunction for patent infringement against Bolb, Inc., a UV LED
Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution21.9.2023 15:00:00 CEST | Press release
Boomi™, the intelligent connectivity and automation leader, today announced the Boomi World Tour, a premiere series of exclusive, in-person events bringing together Boomi customers, prospects, and partners to hear directly from Boomi leadership, industry experts, and visionaries on how organizations can leave complexity behind and synchronize everything, everywhere, with AI-driven integration and automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230921479137/en/ Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution (Graphic: Business Wire) The Boomi World Tour is a series of 10 events over eight weeks, including three Partner Summits designed especially for Boomi partners, global systems integrators, and OEMs. The tour kicks off in Menlo Park, CA, October 3-4, 2023, where attendees will have opportunities to connect and learn throughout the tw
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom